Haemonetics Corporation
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $903.9M | $886.1M | $908.8M | $910.4M | $938.5M | $892.0M | $727.8M | $676.7M |
| Cost of Revenue | $492.0M | $507.6M | $502.9M | $476.0M | $470.1M | $463.9M | $358.6M | $321.5M |
| Gross Profit | $411.9M | $378.5M | $405.9M | $434.4M | $468.4M | $428.1M | $369.2M | $355.2M |
| Gross Margin | 45.6% | 42.7% | 44.7% | 47.7% | 49.9% | 48.0% | 50.7% | 52.5% |
| Operating Expenses | ||||||||
| Research & Development | $39.2M | $37.6M | $45.0M | $54.2M | $54.2M | $44.4M | $36.8M | $32.7M |
| SG&A Expense | $316.5M | $301.7M | $317.2M | $337.2M | $366.0M | $323.1M | $243.7M | $213.9M |
| Operating Income | $56.2M | $-19.4M | $-43.9M | $40.5M | $46.4M | $56.4M | $88.8M | $110.5M |
| Operating Margin | 6.2% | -2.2% | -4.8% | 4.5% | 4.9% | 6.3% | 12.2% | 16.3% |
| Interest Expense | $7.7M | — | — | — | — | — | — | $6.0K |
| Pretax Income | $59.6M | $-27.5M | $-53.4M | $31.2M | $36.4M | $49.9M | $89.5M | $110.1M |
| Income Tax Expense | $14.1M | $-1.2M | $2.2M | $14.3M | $1.3M | $11.1M | $22.6M | $30.1M |
| Net Income | $45.6M | $-26.3M | $-55.6M | $16.9M | $35.1M | $38.8M | $66.9M | $80.0M |
| Net Margin | 5.0% | -3.0% | -6.1% | 1.9% | 3.7% | 4.3% | 9.2% | 11.8% |
| EPS (Basic) | $0.86 | $-0.51 | $-1.09 | $0.33 | $0.68 | $0.76 | $1.32 | $1.59 |
| EPS (Diluted) | $0.85 | $-0.51 | $-1.09 | $0.32 | $0.67 | $0.74 | $1.30 | $1.56 |
| Shares Outstanding (Basic) | 52.8M | 51.5M | 50.9M | 51.5M | 51.6M | 51.3M | 50.7M | 50.2M |
| Shares Outstanding (Diluted) | 53.5M | 51.5M | 50.9M | 52.1M | 52.4M | 52.3M | 51.6M | 51.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |